{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:08:35Z","timestamp":1793981315102,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40265-020-01260-9","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T12:02:46Z","timestamp":1580385766000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Dulaglutide: A Review in Type 2 Diabetes"],"prefix":"10.1007","volume":"80","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"8","key":"1260_CR1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11892-019-1171-0","volume":"19","author":"J-I Shin","year":"2019","unstructured":"Shin J-I. Second-line glucose-lowering therapy for type 2 diabetes mellitus. Curr Diab Rep. 2019;19(8):54.","journal-title":"Curr Diab Rep."},{"key":"1260_CR2","unstructured":"International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. 2017. https:\/\/www.idf.org. Accessed 11 Nov 2019."},{"issue":"Suppl 1","key":"1260_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2337\/dc19-S010","volume":"4","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of diabetes care. Diabetes Care. 2019;4(Suppl 1):103\u201323.","journal-title":"Diabetes Care"},{"key":"1260_CR4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63:221\u20138.","journal-title":"Diabetologia"},{"key":"1260_CR5","unstructured":"European Medicines Agency. Trulicity (Dulaglutide): EU summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/. Accessed 10 Dec 2019."},{"key":"1260_CR6","unstructured":"Eli Lilly and Company. Trulicity (Dulaglutide): US prescribing information. 2019. https:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf. Accessed 21 Oct 2019."},{"issue":"10193","key":"1260_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"6","key":"1260_CR8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40259-015-0143-4","volume":"29","author":"CB Burness","year":"2015","unstructured":"Burness CB, Scott LJ. Dulaglutide: a review in type 2 diabetes. BioDrugs. 2015;29(6):407\u201318.","journal-title":"BioDrugs"},{"issue":"4","key":"1260_CR9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731\u20137.","journal-title":"Hypertension"},{"issue":"8","key":"1260_CR10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrin. 2018;6(8):605\u201317.","journal-title":"Lancet Diabetes Endocrin."},{"issue":"5","key":"1260_CR11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrin. 2018;6(5):370\u201381.","journal-title":"Lancet Diabetes Endocrin."},{"issue":"7","key":"1260_CR12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","volume":"19","author":"P Pozzilli","year":"2017","unstructured":"Pozzilli P, Norwood P, Jodar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024\u201331.","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"1260_CR13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","volume":"18","author":"KM Dungan","year":"2016","unstructured":"Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475\u201382.","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"1260_CR14","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, Povedano ST, Manghi FP. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168\u201378.","journal-title":"Diabetes Care"},{"issue":"8","key":"1260_CR15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","volume":"37","author":"M Nauck","year":"2014","unstructured":"Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149\u201358.","journal-title":"Diabetes Care"},{"issue":"9951","key":"1260_CR16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"K Dungan","year":"2014","unstructured":"Dungan K, Povedano ST, Forst T. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349\u201357.","journal-title":"Lancet"},{"issue":"8","key":"1260_CR17","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","volume":"37","author":"C Wysham","year":"2014","unstructured":"Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159\u201367.","journal-title":"Diabetes Care"},{"issue":"12","key":"1260_CR18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","volume":"38","author":"F Giorgino","year":"2015","unstructured":"Giorgino F, Benroubi M, Sun JH. Efficacy and safety of once weekly dulaglutide vs insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241\u20139.","journal-title":"Diabetes Care"},{"issue":"9982","key":"1260_CR19","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","volume":"385","author":"L Blonde","year":"2015","unstructured":"Blonde L, Jendle J, Gross J. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057\u201366.","journal-title":"Lancet"},{"issue":"10","key":"1260_CR20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/dom.12540","volume":"17","author":"E Araki","year":"2015","unstructured":"Araki E, Inagaki N, Tanizawa Y, et al. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and\/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17(10):994\u20131002.","journal-title":"Diabetes Obes Metab."},{"issue":"10","key":"1260_CR21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/dom.12534","volume":"17","author":"J Miyagawa","year":"2015","unstructured":"Miyagawa J, Odawara M, Takamura T, et al. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17(10):974\u201383.","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"1260_CR22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/dom.13340","volume":"20","author":"YH Chen","year":"2018","unstructured":"Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab. 2018;20(9):2121\u201330.","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"1260_CR23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/dom.13506","volume":"21","author":"W Wang","year":"2019","unstructured":"Wang W, Nevarez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and\/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019;21(2):234\u201343.","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"1260_CR24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s13300-019-0625-3","volume":"10","author":"R Gentilella","year":"2019","unstructured":"Gentilella R, Romera I, Nicolay C, et al. Change in HbA1c across the baseline HbA1c range in type 2 diabetes patients receiving once-weekly dulaglutide versus other incretin agents. Diabetes Ther. 2019;10(3):1113\u201325.","journal-title":"Diabetes Ther."},{"issue":"2","key":"1260_CR25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/dom.13086","volume":"20","author":"B Gallwitz","year":"2018","unstructured":"Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20(2):409\u201318.","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"1260_CR26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/dom.12687","volume":"18","author":"MA Boustani","year":"2016","unstructured":"Boustani MA, Pittman IT, Yu M, et al. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged \u226565 and %3c65 years. Diabetes Obes Metab. 2016;18(8):820\u20138.","journal-title":"Diabetes Obes Metab."},{"key":"1260_CR27","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1111\/dom.13853","volume":"12","author":"R Gentilella","year":"2019","unstructured":"Gentilella R, Sesti G, Vazquez L, et al. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. Diabetes Obes Metab. 2019;12:2660\u20136.","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"1260_CR28","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.4158\/EP161337.OR","volume":"22","author":"JA Davidson","year":"2016","unstructured":"Davidson JA, Manghi FP, Yu M, et al. Efficacy and safety of dulaglutide in Hispanic\/Latino patients with type 2 diabetes in the AWARD clinical program. Endocr Pract. 2016;22(12):1406\u201314.","journal-title":"Endocr Pract."},{"issue":"8","key":"1260_CR29","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1111\/dom.13313","volume":"20","author":"C Mathieu","year":"2018","unstructured":"Mathieu C, Del Prato S, Botros FT, et al. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. Diabetes Obes Metab. 2018;20(8):2023\u20138.","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"1260_CR30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849\u201358.","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"1260_CR31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/dom.13844","volume":"21","author":"F Giorgino","year":"2019","unstructured":"Giorgino F, Yu M, Haupt A, et al. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: a post hoc analysis of the AWARD-2 clinical trial. Diabetes Obes Metab. 2019;21(11):2570\u20135.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"1260_CR32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrin. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrin."},{"issue":"1","key":"1260_CR33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/dom.12575","volume":"18","author":"KM Dungan","year":"2016","unstructured":"Dungan KM, Raz I, Skrivanek Z, et al. Achieving the composite endpoint of glycated haemoglobin %3c\u20097.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes Obes Metab. 2016;18(1):49\u201355.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"1260_CR34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dom.12624","volume":"18","author":"M Yu","year":"2016","unstructured":"Yu M, Van Brunt K, Varnado OJ, et al. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18(4):419\u201324.","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"1260_CR35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/dom.12527","volume":"17","author":"M Reaney","year":"2015","unstructured":"Reaney M, Yu M, Lakshmanan M, et al. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17(9):896\u2013903.","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"1260_CR36","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.clinthera.2017.10.002","volume":"39","author":"M Yu","year":"2017","unstructured":"Yu M, Brunt KV, Milicevic Z, et al. Patient-reported outcomes in patients with type 2 diabetes treated with dulaglutide added to titrated insulin glargine (AWARD-9). Clin Ther. 2017;39(11):2284\u201395.","journal-title":"Clin Ther."},{"issue":"6","key":"1260_CR37","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/dom.13658","volume":"21","author":"M Fuechtenbusch","year":"2019","unstructured":"Fuechtenbusch M, Aberle J, Heitmann E, et al. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: a post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups. Diabetes Obes Metab. 2019;21(6):1340\u20138.","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"1260_CR38","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/dom.13252","volume":"20","author":"KM Pantalone","year":"2018","unstructured":"Pantalone KM, Patel H, Yu M, et al. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes Metab. 2018;20(6):1461\u20139.","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"1260_CR39","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","volume":"21","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diabetes Obes Metab. 2019;21(6):1493\u20137.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"1260_CR40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/dom.13603","volume":"21","author":"R Mody","year":"2018","unstructured":"Mody R, Huang Q, Yu M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab. 2018;21(4):920\u20139.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"1260_CR41","doi-asserted-by":"crossref","first-page":"e000884","DOI":"10.1136\/bmjdrc-2019-000884","volume":"7","author":"R Mody","year":"2019","unstructured":"Mody R, Huang Q, Yu M, et al. Clinical and economic outcomes among injection-naive patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL study. BMJ Open Access Res Care. 2019;7(1):e000884.","journal-title":"BMJ Open Access Res Care."},{"issue":"Supplement 1","key":"1260_CR42","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2337\/db19-1259-P","volume":"68","author":"REEMA MODY","year":"2019","unstructured":"Mody R, Huang Q, Yu M, et al. Adherence and persistence for dulaglutide (DU) vs basal insulin (BI) in injection-naive patients with type 2 diabetes (T2D): the DISPEL\u2122 study [abstract no 1259-P]. Diabetes. 2019;68(Suppl 1).","journal-title":"Diabetes"},{"issue":"3","key":"1260_CR43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s13300-019-0615-5","volume":"10","author":"V Divino","year":"2019","unstructured":"Divino V, Boye KS, Lebrec J, et al. GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019;10(3):1067\u201388.","journal-title":"Diabetes Ther."},{"issue":"5","key":"1260_CR44","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/03007995.2018.1538011","volume":"35","author":"T Otto","year":"2019","unstructured":"Otto T, Myland M, Jung H, et al. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. Curr Med Res Opin. 2019;35(5):893\u2013901.","journal-title":"Curr Med Res Opin."},{"issue":"7","key":"1260_CR45","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/dom.12902","volume":"19","author":"C Alatorre","year":"2017","unstructured":"Alatorre C, Fernandez Lando L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953\u201361.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"1260_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.13028","volume":"20","author":"HC Gerstein","year":"2018","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42\u20139.","journal-title":"Diabetes Obes Metab."},{"issue":"10193","key":"1260_CR47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131\u20138.","journal-title":"Lancet"},{"key":"1260_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-016-0355-z","volume":"15","author":"KC Ferdinand","year":"2016","unstructured":"Ferdinand KC, Botros FT, Atisso CM, et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15:38.","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"1260_CR49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2337\/dc16-0984","volume":"40","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647\u201354.","journal-title":"Diabetes Care"},{"issue":"3","key":"1260_CR50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/dom.12816","volume":"19","author":"KR Tuttle","year":"2017","unstructured":"Tuttle KR, McKinney TD, Davidson JA, et al. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metabol. 2017;19(3):436\u201341.","journal-title":"Diabetes Obes Metabol."},{"key":"1260_CR51","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2019. https:\/\/www.nice.org.uk\/guidance\/ng28. Accessed 11 Nov 2019."},{"issue":"Suppl 1","key":"1260_CR52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42(Suppl 1):90\u2013102.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1260_CR53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2337\/dc19-S006","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Glycemic targets: standards of medical care\u20142019. Diabetes Care. 2019;42(Suppl 1):61\u201370.","journal-title":"Diabetes Care"},{"issue":"1","key":"1260_CR54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/CS-2018-0535","volume":"25","author":"AJ Garber","year":"2019","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2019 executive summary. Endocrine Pract. 2019;25(1):69\u2013100.","journal-title":"Endocrine Pract."},{"issue":"4","key":"1260_CR55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347\u201357.","journal-title":"N Engl J Med."},{"issue":"1","key":"1260_CR56","doi-asserted-by":"crossref","first-page":"e3070","DOI":"10.1002\/dmrr.3070","volume":"35","author":"R Gentilella","year":"2019","unstructured":"Gentilella R, Pechtner V, Corcos A, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35(1):e3070.","journal-title":"Diabetes Metab Res Rev."},{"key":"1260_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13902","author":"LS Matza","year":"2019","unstructured":"Matza LS, Boye KS, Stewart KD, et al. Crossover clinical trial assessing patient PREFERence between the dulaglutide pen and semaglutide pen (PREFER). Diabetes Obes Met. 2019. https:\/\/doi.org\/10.1111\/dom.13902.","journal-title":"Diabetes Obes Met."},{"issue":"8","key":"1260_CR58","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2018.1465903","volume":"34","author":"LS Matza","year":"2018","unstructured":"Matza LS, Boye KS, Currie BM, et al. Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Curr Med Res Opin. 2018;34(8):1457\u201364.","journal-title":"Curr Med Res Opin."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01260-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01260-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01260-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:10:17Z","timestamp":1611879017000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01260-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01260-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"30 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Lesley Scott is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}